#ZeriaPharmaceutical

Effective April 9, 2026, Mr. Kenichi Suzuki is promoted from Executive Officer to Senior Executive Officer while continuing as General Manager of Corporate Planning.

From the March 2026 record date, the shareholder benefit F course content for shareholders holding 1,000 shares or more will be changed to the “Iona R Double Action Cream 2-piece set.”

Consolidated net sales for the third quarter of fiscal year ending March 2026 were JPY 64,077 million (down 1.1% YoY), operating income was JPY 8,566 million (down 16.4% YoY), and net income attributable to owners of parent for the quarter was JPY 5,554 million (down 32.5% YoY).

Zeria Pharmaceutical Co., Ltd. announced plans to cancel 1,000,000 shares of common stock (1.96% of the total outstanding shares) on February 25, 2026.